These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vivo age dependency of unfractionated heparin in infants and children. Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072 [TBL] [Abstract][Full Text] [Related]
3. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P Thromb Haemost; 2010 May; 103(5):1085-90. PubMed ID: 20174762 [TBL] [Abstract][Full Text] [Related]
5. Clinical use of unfractionated heparin therapy in children: time for change? Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P Br J Haematol; 2010 Sep; 150(6):674-8. PubMed ID: 20629660 [TBL] [Abstract][Full Text] [Related]
6. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. van den Besselaar AM; Meeuwisse-Braun J; Bertina RM Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357 [TBL] [Abstract][Full Text] [Related]
7. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions. Hoppensteadt DA; Walenga JM; Fareed J Semin Thromb Hemost; 1985 Apr; 11(2):112-20. PubMed ID: 3898369 [TBL] [Abstract][Full Text] [Related]
8. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin. Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794 [TBL] [Abstract][Full Text] [Related]
9. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate. Wang ZM; Li L; Li B; Guo SY Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476 [TBL] [Abstract][Full Text] [Related]
10. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K; Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600 [TBL] [Abstract][Full Text] [Related]
11. Refinement and feasibility testing of a manual micro-method for protamine titration. Newall F; Johnston L; Ignjatovic V; Summerhayes R; Monagle P Int J Lab Hematol; 2009 Aug; 31(4):457-61. PubMed ID: 18371057 [TBL] [Abstract][Full Text] [Related]
12. Monitoring of heparin therapy with the activated partial thromboplastin time and chromogenic substrate assays. Fey MF; Lang M; Furlan M; Beck EA Thromb Haemost; 1987 Oct; 58(3):853-5. PubMed ID: 3481140 [TBL] [Abstract][Full Text] [Related]
13. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Kroon C; ten Hove WR; de Boer A; Kroon JM; van der Pol JM; Harthoorn-Lasthuizen EJ; Schoemaker HC; van der Meer FJ; Cohen AF Circulation; 1992 Nov; 86(5):1370-5. PubMed ID: 1423948 [TBL] [Abstract][Full Text] [Related]
14. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate? Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432 [TBL] [Abstract][Full Text] [Related]
15. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects. Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405 [TBL] [Abstract][Full Text] [Related]
16. The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults. Ignjatovic V; Summerhayes R; Yip YY; Monagle P Thromb Res; 2008; 122(5):709-14. PubMed ID: 18384841 [TBL] [Abstract][Full Text] [Related]
17. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays. Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195 [TBL] [Abstract][Full Text] [Related]
18. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Kitchen S; Theaker J; Preston FE Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006 [TBL] [Abstract][Full Text] [Related]
19. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Bratt G; Törnebohm E; Lockner D; Bergström K Thromb Haemost; 1985 Apr; 53(2):208-11. PubMed ID: 4024029 [TBL] [Abstract][Full Text] [Related]
20. The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times. Brack MJ; More RS; Hubner PJ; Gershlick AH Blood Coagul Fibrinolysis; 1993 Feb; 4(1):183-6. PubMed ID: 8457649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]